サルコペニア:パイプラインレビュー2019下半期

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GDATA9120328)
◆英語タイトル:Sarcopenia - Pipeline Review, H2 2019
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GDATA9120328
◆発行日:2019年11月
◆調査対象地域:グローバル
◆産業分野:製薬及び医療
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[サルコペニア:パイプラインレビュー2019下半期]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Sarcopenia – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia – Pipeline Review, H2 2019, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Sarcopenia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia – Overview
Sarcopenia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia – Companies Involved in Therapeutics Development
Biophytis SA
Faraday Pharmaceuticals Inc
Helixmith Co Ltd
Immusoft Corp
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
PhaseBio Pharmaceuticals Inc
ST Pharm Co Ltd
Teijin Pharma Ltd
Sarcopenia – Drug Profiles
ARM-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Muscle Wasting Disorders and Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit SARM1 for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-504 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1023 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NNMT for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium iodide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia – Dormant Projects
Sarcopenia – Discontinued Products
Sarcopenia – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Biophytis files protocol amendment to optimize the SARA-INT phase 2b clinical trial for sarcopenia
Oct 04, 2019: Biophytis opens 22nd clinical site in the SARA-INT phase 2b trial of Sarconeos (BIO101) for the treatment of sarcopenia
Feb 18, 2019: Biophytis announces three oral and one poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research
Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting
Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases
Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia
May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)
Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sarcopenia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Sarcopenia - Pipeline by Biophytis SA, H2 2019
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by Helixmith Co Ltd, H2 2019
Sarcopenia - Pipeline by Immusoft Corp, H2 2019
Sarcopenia - Pipeline by Keren Therapeutics, H2 2019
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2019
Sarcopenia - Pipeline by Neurotune AG, H2 2019
Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by ST Pharm Co Ltd, H2 2019
Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2019
Sarcopenia - Dormant Projects, H2 2019
Sarcopenia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Sarcopenia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Sarcopenia, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products under Development by Universities/Institutes, H2 2019 12
Number of Products by Targets, H2 2019 15
Number of Products by Stage and Targets, H2 2019 15
Number of Products by Mechanism of Actions, H2 2019 17
Number of Products by Stage and Mechanism of Actions, H2 2019 17
Number of Products by Routes of Administration, H2 2019 19
Number of Products by Stage and Routes of Administration, H2 2019 19
Number of Products by Molecule Types, H2 2019 21
Number of Products by Stage and Molecule Types, H2 2019 21

*** 掲載企業 ***

Biophytis SA
Faraday Pharmaceuticals Inc
Helixmith Co Ltd
Immusoft Corp
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
PhaseBio Pharmaceuticals Inc
ST Pharm Co Ltd
Teijin Pharma Ltd

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • サファイア半導体の世界市場2016-2020
    About Sapphires Sapphire is a versatile material that is used in LEDs and consumer electronics. It is used in a wide range of end markets due to attributes such as durability, light transmission, chemical inertness, thermal insulation, hardness, and resistance to physical damage and chemical erosion …
  • ボート及び船通信の世界市場:成長・動向・予測(2020年-2025年)
    The Boat and Ship telematics market is expected to exhibit a growth rate of over 20% during the forecast period (2020 - 2025). - With the rapid increase in international sea trade, new opportunities are not only arising for ship and vessel operators but also brings new challenges such as maintaining …
  • 電流データロガーの世界市場:販売動向2017
    Notes:Sales, means the sales volume of Current Data Loggers Revenue, means the sales value of Current Data Loggers This report studies sales (consumption) of Current Data Loggers in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries …
  • ポーランドのカーボンブラック市場2016-2020
    About The report brings together facts and figures about carbon black market in Poland covering period of 2009-2019. Statistics, experts’ opinions and estimations are given. The report about carbon black market in Poland covers: - manufacturers capacity, production volumes - company profiles - consu …
  • プロメカルブの世界市場2020
    The Global Promecarb (CAS 2631-37-0) Industry 2020 Market Research Report is a professional and in-depth study on the current state of the Promecarb industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structu …
  • 金属加工液のアジア太平洋市場2020-2083
    KEY FINDINGS The metalworking fluids market of Asia Pacific is anticipated to grow significantly and reach the highest CAGR of 3.60%, due to rapid economic development, and the introduction of various favorable government policies such as ‘Smart Cities’ and FDI. MARKET INSIGHTS In order to understan …
  • 3,4,5-トリメトキシトルエンの世界市場2020
    The Global 3,4,5-Trimethoxy Toluene (CAS 6443-69-2) Industry 2020 Market Research Report is a professional and in-depth study on the current state of the 3,4,5-Trimethoxy Toluene industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applicati …
  • 硫酸ビスマスの世界市場2018
    Bismuth Sulfate Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, German …
  • アルミニウム合金ホイールの世界市場2019-2023
    About this market Increased benefits of aluminum in alloy wheels over conventional materials is a key factor driving the growth of the market. Alloy wheels are highly resistant to oxidation thus, they are less prone to rust and corrosion. Aluminum is a good dispenser of heat compared to pure metals, …
  • 強迫性障害(Obsessive-Compulsive Disorder):治療薬市場2019(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)
    SUMMARY DelveInsight’s Report, “Obsessive-Compulsive Disorder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Ob …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDATA9120328 )"サルコペニア:パイプラインレビュー2019下半期" (英文:Sarcopenia - Pipeline Review, H2 2019)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。